Skip to main content

Advertisement

Log in

KIT expression and methylation in medulloblastoma and PNET cell lines and tumors

  • Laboratory Investigation - Human/Animal Tissue
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

The stem cell factor/kit tyrosine kinase receptor pathway is related to tumor growth and progression in several cancers including Ewing sarcoma, a peripheral PNET (pPNET). Identifying additional groups of tumors that may use the pathway is important as they might be responsive to imatinib mesylate treatment. MB and central PNET (cPNET) are embryonal tumors of the CNS that share similar undifferentiated morphology with Ewing sarcomas and display aggressive clinical behavior. cPNET outcome is significantly lower than MB outcome, even for localized tumors treated with high-risk MB therapy. The elucidation of signaling pathways involved in MB and cPNET pathogenesis, and the discovery of new therapeutic targets is necessary to improve the treatment of these neoplasms. We analyzed KIT expression in 2 MB, one pPNET, one cPNET and 2 rhabdomyosarcoma (RMS) cell lines. Also, in 13 tumor samples (12 MB and one cPNET), we found KIT overexpression in the most aggressive cell lines (metastatic MB and pPNET). Hypermethylation of KIT was clear in the RMS non-expressing cell lines. Among MB tumors, we could see variable levels of KIT expression; a subset of them (25%) might be related in its growth pattern to KIT up-regulation. No methylated KIT was detected in the tumors expressing the lowest levels of KIT. Our results point to methylation as an epigenetic regulatory mechanism for KIT inhibition only in the KIT non-expressing RMS cell lines, and neither in the rest of the cell lines nor in the tumor samples.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

Abbreviations

CNS:

Central nervous system

EWS:

Ewing sarcoma

MB:

Medulloblastoma

MCA-Meth:

Melting curve analysis-methylation

MSP:

Methylation specific PCR

PNET:

Primitive neuroectodermal tumor

SCF:

Stem cell factor

RMS:

Rhabdomyosarcoma

References

  1. Smithey BE, Pappo AS, Hill DA (2002) C-kit expression in pediatric solid tumors: a comparative immunohistochemical study. Am J Surg Pathol 26:486–492

    Article  PubMed  Google Scholar 

  2. Zwerner JP, May WA (2001) PDGF-C is an EWS/FLI induced transforming growth factor in Ewing family tumors. Oncogene 20:626–633

    Article  PubMed  CAS  Google Scholar 

  3. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97–109

    Article  PubMed  Google Scholar 

  4. Kleihues P, Sobin LH (2000) World Health Organization classification of tumors. Cancer 88:2887

    Article  PubMed  CAS  Google Scholar 

  5. Provias JP, Becker LE (1996) Cellular and molecular pathology of medulloblastoma. J Neurooncol 29:35–43

    Article  PubMed  CAS  Google Scholar 

  6. Biegel JA, Pollack IF (2004) Molecular analysis of pediatric brain tumors. Curr Oncol Rep 6:445–452

    Article  PubMed  Google Scholar 

  7. Bar EE, Stearns D (2008) New developments in medulloblastoma treatment: the potential of a cyclopamine-lovastatin combination. Expert Opin Investig Drugs 17:185–195

    Article  PubMed  CAS  Google Scholar 

  8. Marino S (2005) Medulloblastoma: developmental mechanisms out of control. Trends Mol Med 11:17–22

    Article  PubMed  CAS  Google Scholar 

  9. Reddy AT, Janss AJ, Phillips PC, Weiss HL, Packer RJ (2000) Outcome for children with supratentorial primitive neuroectodermal tumors treated with surgery, radiation, and chemotherapy. Cancer 88:2189–2193

    Article  PubMed  CAS  Google Scholar 

  10. Fan X, Eberhart CG (2008) Medulloblastoma stem cells. J Clin Oncol 26:2821–2827

    Article  PubMed  CAS  Google Scholar 

  11. Fan X, Matsui W, Khaki L, Stearns D, Chun J, Li YM, Eberhart CG (2006) Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res 66:7445–7452

    Article  PubMed  CAS  Google Scholar 

  12. Fan X, Mikolaenko I, Elhassan I, Ni X, Wang Y, Ball D, Brat DJ, Perry A, Eberhart CG (2004) Notch1 and notch2 have opposite effects on embryonal brain tumor growth. Cancer Res 64:7787–7793

    Article  PubMed  CAS  Google Scholar 

  13. Li LC, Dahiya R (2002) MethPrimer: designing primers for methylation PCRs. Bioinformatics 18:1427–1431

    Article  PubMed  CAS  Google Scholar 

  14. Lorente A, Mueller W, Urdangarin E, Lazcoz P, von Deimling A, Castresana JS (2008) Detection of methylation in promoter sequences by melting curve analysis-based semiquantitative real time PCR. BMC Cancer 8:61

    Article  PubMed  Google Scholar 

  15. Chilton-Macneill S, Ho M, Hawkins C, Gassas A, Zielenska M, Baruchel S (2004) C-kit expression and mutational analysis in medulloblastoma. Pediatr Dev Pathol 7:493–498

    Article  PubMed  CAS  Google Scholar 

  16. McCabe MG, Ichimura K, Liu L, Plant K, Backlund LM, Pearson DM, Collins VP (2006) High-resolution array-based comparative genomic hybridization of medulloblastomas and supratentorial primitive neuroectodermal tumors. J Neuropathol Exp Neurol 65:549–561

    Article  PubMed  CAS  Google Scholar 

  17. Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ (2000) Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 96:925–932

    PubMed  CAS  Google Scholar 

  18. Chao J, Budd GT, Chu P, Frankel P, Garcia D, Junqueira M, Loera S, Somlo G, Sato J, Chow WA (2010) Phase II clinical trial of imatinib mesylate in therapy of KIT and/or PDGFRalpha-expressing Ewing sarcoma family of tumors and desmoplastic small round cell tumors. Anticancer Res 30:547–552

    PubMed  CAS  Google Scholar 

  19. Yamamoto K, Tojo A, Aoki N, Shibuya M (1993) Characterization of the promoter region of the human c-kit proto-oncogene. Jpn J Cancer Res 84:1136–1144

    PubMed  CAS  Google Scholar 

  20. Vandenbark GR, Chen Y, Friday E, Pavlik K, Anthony B, deCastro C, Kaufman RE (1996) Complex regulation of human c-kit transcription by promoter repressors, activators, and specific myb elements. Cell Growth Differ 7:1383–1392

    PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The authors are grateful to Laura Stokes for help with editing the manuscript. M. Enguita-Germán, M. Gurrea and P. Schiapparelli thank the Asociación de Amigos de la Universidad de Navarra and the Departamento de Educación del Gobierno de Navarra for the fellowships received. J.S. Castresana is grateful to the Asociación Española de Pediatría for the VIII Premio Nutribén de Investigación Pediátrica, and the Sociedad Española de Hematología y Oncología Pediátricas, Madrid. J.S. Castresana was supported in part by grants from the Departmento de Salud del Gobierno de Navarra (9/07), Caja Navarra (08/13912), and Fundación Universitaria de Navarra, Pamplona; and Fondo de Investigación Sanitaria (PI081849), Madrid. X. Fan would like to acknowledge grant support from Accelerate Brain Cancer Cure Project Award, American Brain Tumor Association Translational Grant, and Voices Against Brain Cancer Research Grant.

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to Xing Fan or Javier S. Castresana.

Additional information

Mikel Gurrea and Paula Schiapparelli contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Enguita-Germán, M., Gurrea, M., Schiapparelli, P. et al. KIT expression and methylation in medulloblastoma and PNET cell lines and tumors. J Neurooncol 103, 247–253 (2011). https://doi.org/10.1007/s11060-010-0391-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-010-0391-6

Keywords

Navigation